Evaluasi Ekonomi Parsial antara Pemberian Terapi Rivaroxaban dan Terapi Kombinasi (Unfractionated Heparin + Warfarin) untuk Pengobatan Trombosis Vena Dalam pada Pasien Kanker di Rumah Sakit Kanker Dharmais
Abstract
Keywords
References
Adnyana IWL, Suega K, dan Bakta IM. 2013. Trombosis Vena Dalam. Pendidikan Kedokteran Berkelanjutan (PKB) XXI. Fakultas Kedokteran Universitas Udayana.
Bamber, L., et al. 2015. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis Journal, 13, 20. http://doi.org/10.1186/s12959-015-0051-3
Coleman, C. I., et al. 2016. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism, Journal of Medical Economics, DOI: 10.1080/13696998.2016.1243544
Coleman, C. I., Bunz, T. J., & Turpie, A. G. G. 2017. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost 2017; 117: 1841–1847. https://doi.org/10.1160/TH17-03-0210
Drummond, M. F., et al. 2015. Methods for the Economic Evaluation of Health Care Programmes. Fourth Edition. New York: Oxford University Press.
Info BPJS Kesehatan. 2014. Perubahan Tarif INA-CBGs Membuat Biaya Kesehatan Lebih Efektif. Edisi VIII. Jakarta: BPJS Kesehatan. Available from: https://bpjs-kesehatan.go.id/bpjs/dmdocuments/2b67b6556b028d910d2ee8df4245e886.pdf
Larsen, Torben B, et al. 2017. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. The Lancet Haematology, Volume 4, Issue 5, e237-e244. DOI: 10.1016/S2352-3026(17)30054-6
Mantha, Simon, et al. 2017. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43: 166-171. DOI 10.1007/s11239-016-1429-1.
Margolis, J. M., et al. 2016. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. Journal of the American Heart Association, 5(10). Available from: http://jaha.ahajournals.org/content/5/10/e003788
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2016. Panduan Praktik Klinis dan Clinical Pathway Penyakit Jantung dan Pembuluh Darah (Edisi Pertama). Jakarta: PERKI.
Scott, D., et al. 2010. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 363(26), 2499–2510. https://doi.org/10.1056/NEJMoa1007903
Seaman, C.D., Smith K.J., dan Ragni M.V. 2013. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective. Thrombosis Research Volume 132, Issue 6, pp. 647-651. DOI: 10.1016/j.thromres.2013.09.015
Sinombor, Sonya Hellen. 2010. Pengobatan Sederhana untuk Pasien DVT. http://nasional.kompas.com/read/2010/10/28/02432339/about.html
Yaznil MR, Sahil MF, dan Lubis ND. 2010. Prevalensi Trombosis Vena Dalam (Deep Vein Thrombosis) dengan Compression Ultrasound B-Mode Image pada Pasien Tumor Ginekologi Resiko Tinggi dan Resiko Rendah di RS H. Adam Malik Medan. Medan: Fakultas Kedokteran Universitas Sumatera Utara.
DOI: 10.7454/eki.v5i1.3773
Refbacks
- There are currently no refbacks.